614 related articles for article (PubMed ID: 17977894)
1. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells.
Habib-Agahi M; Phan TT; Searle PF
Int Immunol; 2007 Dec; 19(12):1383-94. PubMed ID: 17977894
[TBL] [Abstract][Full Text] [Related]
2. 4-1BBL costimulation retrieves CD28 expression in activated T cells.
Habib-Agahi M; Jaberipour M; Searle PF
Cell Immunol; 2009; 256(1-2):39-46. PubMed ID: 19217084
[TBL] [Abstract][Full Text] [Related]
3. Co-stimulatory pathways controlling activation and peripheral tolerance of human CD4+CD28- T cells.
Park W; Weyand CM; Schmidt D; Goronzy JJ
Eur J Immunol; 1997 May; 27(5):1082-90. PubMed ID: 9174596
[TBL] [Abstract][Full Text] [Related]
4. Preferential T cell expansion by artificial antigen presenting cells expressing 4-1BBL alone or in combination with CD80 or CD86.
Habib-Agahi M; Jaberipour M; Phan TT; Searle PF
Iran J Immunol; 2008 Sep; 5(3):136-47. PubMed ID: 18791280
[TBL] [Abstract][Full Text] [Related]
5. Modulation of cell cycle progression by CTLA4-CD80/CD86 interactions on CD4+ T cells depends on strength of the CD3 signal: critical role for IL-2.
Mukherjee S; Ahmed A; Malu S; Nandi D
J Leukoc Biol; 2006 Jul; 80(1):66-74. PubMed ID: 16624934
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of CD80, CD86 and CD70 on T cells from HIV-infected individuals upon activation in vitro: regulation by CD4+ T cells.
Wolthers KC; Otto SA; Lens SM; Kolbach DN; van Lier RA; Miedema F; Meyaard L
Eur J Immunol; 1996 Aug; 26(8):1700-6. PubMed ID: 8765009
[TBL] [Abstract][Full Text] [Related]
7. CTLA4-CD80/CD86 interactions on primary mouse CD4+ T cells integrate signal-strength information to modulate activation with Concanavalin A.
Mukherjee S; Ahmed A; Nandi D
J Leukoc Biol; 2005 Jul; 78(1):144-57. PubMed ID: 15788440
[TBL] [Abstract][Full Text] [Related]
8. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL.
Lanier LL; O'Fallon S; Somoza C; Phillips JH; Linsley PS; Okumura K; Ito D; Azuma M
J Immunol; 1995 Jan; 154(1):97-105. PubMed ID: 7527824
[TBL] [Abstract][Full Text] [Related]
9. Distinct effects of CD86-mediated costimulation on resting versus activated human CD4+ T cells.
Rogers NJ; Game DS; Camara NO; Jackson IM; Lombardi G; Lechler RI
Eur J Immunol; 2005 Oct; 35(10):2909-19. PubMed ID: 16180251
[TBL] [Abstract][Full Text] [Related]
10. Expression of costimulatory molecules CD80 and/or CD86 by a Kaposi's sarcoma tumor cell line induces differential T-cell activation and proliferation.
Foreman KE; Wrone-Smith T; Krueger AE; Nickoloff BJ
Clin Immunol; 1999 Jun; 91(3):345-53. PubMed ID: 10370381
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of CD86/CD28 and CD40/CD154 pathways in regulating monocyte-derived CD80 expression during their interaction with allogeneic endothelium.
Wang P; Liu Z; Wu C; Zhu B; Wang Y; Xu H
Transplant Proc; 2008 Oct; 40(8):2729-33. PubMed ID: 18929847
[TBL] [Abstract][Full Text] [Related]
12. Expression of costimulatory molecules (CD80, CD86, CD28, CD152), accessory molecules (TCR alphabeta, TCR gammadelta) and T cell lineage molecules (CD4+, CD8+) in PBMC of leprosy patients using Mycobacterium leprae antigen (MLCWA) with murabutide and T cell peptide of Trat protein.
Sridevi K; Neena K; Chitralekha KT; Arif AK; Tomar D; Rao DN
Int Immunopharmacol; 2004 Jan; 4(1):1-14. PubMed ID: 14975355
[TBL] [Abstract][Full Text] [Related]
13. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
14. Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecule.
McLellan AD; Starling GC; Williams LA; Hock BD; Hart DN
Eur J Immunol; 1995 Jul; 25(7):2064-8. PubMed ID: 7542604
[TBL] [Abstract][Full Text] [Related]
15. Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells.
Blazar BR; Sharpe AH; Taylor PA; Panoskaltsis-Mortari A; Gray GS; Korngold R; Vallera DA
J Immunol; 1996 Oct; 157(8):3250-9. PubMed ID: 8871619
[TBL] [Abstract][Full Text] [Related]
16. 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses.
Tan JT; Whitmire JK; Ahmed R; Pearson TC; Larsen CP
J Immunol; 1999 Nov; 163(9):4859-68. PubMed ID: 10528187
[TBL] [Abstract][Full Text] [Related]
17. The role of CD80 and CD86 in enhancing CD8(+) cell suppression of HIV replication.
Barker E; Bossart KN; Fujimura SH; Levy JA
Cell Immunol; 1999 Sep; 196(2):95-103. PubMed ID: 10527561
[TBL] [Abstract][Full Text] [Related]
18. Co-stimulation of antigen-specific CD4 T cells by 4-1BB ligand.
Gramaglia I; Cooper D; Miner KT; Kwon BS; Croft M
Eur J Immunol; 2000 Feb; 30(2):392-402. PubMed ID: 10671194
[TBL] [Abstract][Full Text] [Related]
19. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH
Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
[TBL] [Abstract][Full Text] [Related]
20. Functional CD86 (B7-2/B70) is predominantly expressed on Langerhans cells in atopic dermatitis.
Ohki O; Yokozeki H; Katayama I; Umeda T; Azuma M; Okumura K; Nishioka K
Br J Dermatol; 1997 Jun; 136(6):838-45. PubMed ID: 9217814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
